Company Information

  

Address: 34790 Ardentech Court  
City: Fremont 
State: CA 
Zip Code: 94555 
Telephone: (510) 745-1200 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM, technology. In February 2017, we announced positive results from our ZOTRIP pivotal efficacy trial, or ZOTRIP trial, that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. We are focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. ADAM is our proprietary, investigational technology platform designed to offer rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-14.09NAN/E
12/2017-336.40NAN/E
09/2017-440.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.12Total Liab/Total Assets0.61
Net Inc/Total Assets-1.62Total Liab/Inv Cap12.79
Net Inc/Inv Cap-34.00Total Liab/Comm Equity0.05
Pretax Inc/Net SalesNAInterest Coverage Ratio-38.23
Net Inc/Net SalesNACurr Debt/Equity0.95
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.95
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio1.28
Inventory TurnoverNACurrent Ratio1.28
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.26 1.84 2.04 2.19
Operating Income -8.07 -7.35 -7.72 -6.55
Interest Exp 0.14 0.13 0.15 0.21
Pretax Income -8.21 -7.49 -7.87 -6.75
Other Income 0.00 -0.00 0.00 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.21 -7.49 -7.87 -6.75

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 3.54 11.65 19.85 28.23
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 5.51 13.39 21.18 29.39
Net Property, Plant & Equipment 4.41 4.15 4.24 4.80
Total Assets 10.37 18.00 25.88 34.64
Liabilities        
Accounts Payable 5.52 3.77 3.15 2.93
Debt in Current Liabilities 5.16 6.69 6.23 6.12
Total Current Liabilities 10.68 10.46 9.38 9.04
Long-Term Debt NA 0.00 1.95 3.52
Total Liabilities 11.39 10.95 11.65 12.69
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -234.08 -225.87 -218.39 -210.51
Treasury Stock NA NA NA NA
Total Stockholders' Equity -1.02 7.05 14.23 21.96
Total Liabilities and Stockholders' Equity 10.37 18.00 25.88 34.64

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -6.14 -6.16 -6.83 -7.15
Net Cash Provided by Investing Activities -0.45 6.02 0.43 -7.60
Net Cash Provided by Financing Activities -1.53 -1.50 -1.46 -1.44

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20134.25-5.61--
12/20142.86-14.24--
12/20150.31-28.43--
12/20160.00-29.83--
12/20170.00-29.10-336.40
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18465,62046.95




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.